Showing 1-30 of 48 results for "D2390"
Josip Joachim Grah et al.
World journal of surgical oncology, 11, 55-55 (2013-03-19)
Despite huge advances in medicine, glioblastoma multiforme (GBM) remains a highly lethal, fast-growing tumour that cannot be cured by currently available therapies. However, extracranial and extraneural dissemination of GBM is extremely rare, but is being recognised in different imaging studies....
Irshad Ahmad et al.
International journal of biological macromolecules, 79, 193-200 (2015-05-06)
A detailed investigation on the mode of action and binding mechanism of a potent anticancer drug, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DCR) with calf thymus DNA (ctDNA) was carried out. UV-vis and fluorescence spectrophotometry suggested the formation of complex between DCR and ctDNA. The...
Linda Chen et al.
International journal of radiation oncology, biology, physics, 86(4), 616-622 (2013-04-02)
Neural progenitor cells in the subventricular zone (SVZ) have a controversial role in glioblastoma multiforme (GBM) as potential tumor-initiating cells. The purpose of this study was to examine the relationship between radiation dose to the SVZ and survival in GBM...
Elodie Josset et al.
Anticancer research, 33(5), 1845-1851 (2013-05-07)
We have studied the consequences of the combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 and temozolomide on the growth and cell death of the glioblastoma cell line U-87 in vitro. A progressive decrease of cell proliferation was...
Brian J Wilson et al.
Cancer research, 74(15), 4196-4207 (2014-06-18)
The drug efflux transporter ABCB5 identifies cancer stem-like cells (CSC) in diverse human malignancies, where its expression is associated with clinical disease progression and tumor recurrence. ABCB5 confers therapeutic resistance, but other functions in tumorigenesis independent of drug efflux have...
Boris Böll et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(12), 1522-1529 (2013-03-20)
Older patients with Hodgkin lymphoma (HL) account for approximately 20% of all HL patients. ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded as standard of care in these patients. However, little is known on feasibility and efficacy of ABVD...
GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates.
Breen, et al.
Cell Metabolism, 32, 938-950 (2020)
Has targeted therapy for melanoma made chemotherapy obsolete?
Geoffrey T Gibney et al.
The Lancet. Oncology, 14(8), 676-677 (2013-07-03)
Sheng-Hua Chu et al.
Journal of translational medicine, 11, 69-69 (2013-03-22)
Our previous study showed that SLC22A18 downregulation and promoter methylation were associated with the development and progression of glioma and the elevated expression of SLC22A18 was found to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea...
Rimas V Lukas et al.
Tumori, 99(2), e73-e76 (2013-06-12)
Progression of central nervous system (CNS) metastases from small cell lung cancer (SCLC) after radiation therapy is associated with a poor prognosis. We present two cases of patients with progressive CNS metastases from SCLC treated with oral temozolomide and etoposide....
Dariusz Szczepanek et al.
Neurologia i neurochirurgia polska, 47(2), 101-108 (2013-05-08)
The common treatment in patients with newly diagnosed glioblastoma multiforme is the ultimately radical surgical removal of the tumour combined with radiotherapy. This study compared safety and efficacy of radiotherapy alone with radiotherapy combined with temozolomide (TMZ) given before, during...
Reply to A. Koumarianou et al and J. Hadoux et al.
Jennifer A Chan et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(7), 977-978 (2013-04-09)
Yasuto Naoi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 30(1), 145-149 (2003-02-01)
We report the case of a 58-year-old man with metastatic tumors 13 months after the initial surgery for paraganglioma at the left adrenal gland. A CT scan revealed a large tumor at the right scapula and abdominal paraaortic lymph nodes...
Elena Kurenova et al.
Cell cycle (Georgetown, Tex.), 13(16), 2542-2553 (2014-12-09)
Melanoma has the highest mortality rate of all skin cancers and a major cause of treatment failure is drug resistance. Tumors heterogeneity requires novel therapeutic strategies and new drugs targeting multiple pathways. One of the new approaches is targeting the...
Luis Sanchez-Perez et al.
Cancer immunology, immunotherapy : CII, 62(6), 983-987 (2013-04-18)
B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral...
Rachel Grossman et al.
Cancer chemotherapy and pharmacology, 72(1), 93-100 (2013-05-08)
Combining anti-angiogenesis agents with cytotoxic agents for the treatment of malignant gliomas may affect the cytotoxic drug distribution by normalizing the blood-brain barrier (BBB). This study examines the intratumoral concentration of temozolomide (TMZ) in the presence and absence of the...
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.
David Cucchiari et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(14), e240-e242 (2013-04-03)
Heinz-Georg Jahnke et al.
Cancer research, 74(22), 6408-6418 (2014-10-01)
Stage III/IV melanoma remains incurable in most cases due to chemotherapeutic resistance. Thus, predicting and monitoring chemotherapeutic responses in this setting offer great interest. To overcome limitations of existing assays in evaluating the chemosensitivity of dissociated tumor cells, we developed...
Giuseppe Minniti et al.
International journal of radiation oncology, biology, physics, 86(2), 285-291 (2013-05-07)
To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ). Health-related QOL (HRQOL) was assessed by European...
Kee Kiat Yeo et al.
Journal of neurosurgery. Pediatrics, 11(6), 682-686 (2013-04-02)
Cellular hemangioma is a subtype of hemangioma that is associated with cellular immaturity and the potential for recurrence. Intracranial location of these lesions is extremely rare, and definitive treatment often requires radical neurosurgical resection. The authors report a case of...
D Kramer et al.
Cell death & disease, 6, e1634-e1634 (2015-02-13)
The p53 family and its cofactors are potent inducers of apoptosis and form a barrier to cancer. Here, we investigated the impact of the supposedly inhibitory member of the apoptosis-stimulating protein of p53, iASPP, on the activity of the p53...
Michiko Horiguchi et al.
The Journal of pharmacology and experimental therapeutics, 333(3), 782-787 (2010-03-24)
O(6)-methylguanine-DNA methyltransferase (MGMT) plays a crucial role in the defense against the alkylating agent-induced cytotoxic lesion O(6)-alkylguanine in DNA. Although a significant circadian variation in MGMT activity has been found in the liver of mice, the exact mechanism of the...
Mark D Anderson et al.
Oncology (Williston Park, N.Y.), 27(4), 315-320 (2013-06-21)
Abstract: Anaplastic oligodendroglioma (AO) is a rare malignant tumor occurring in adults. Despite early indications of chemosensitivity, no clinical trial had demonstrated a benefit of chemotherapy beyond that of radiotherapy alone. Now, however, the Radiation Therapy Oncology Group (RTOG) 9402...
Fleury Augustin Nsole Biteghe et al.
Journal of photochemistry and photobiology. B, Biology, 211, 111982-111982 (2020-09-01)
Aberrant anti-cancer drug efflux mediated by membrane protein ABC transporters (ABCB5 and ABCG2) is thought to characterize melanoma heterogeneous chemoresistant populations, presumed to have unlimited proliferative and self-renewal abilities. Therefore, this study primarily aimed to investigate whether continuous exposure of...
[Treatment of advanced Hodgkin lymphoma].
S Kreissl et al.
Deutsche medizinische Wochenschrift (1946), 138(23), 1212-1214 (2013-05-31)
O Mizuno
Nihon Naibunpi Gakkai zasshi, 70(9), 1039-1046 (1994-11-20)
A 49-year-old woman had a right adrenalectomy for pheochromocytoma in April 1989. In May 1990 she underwent an operation to remove paraaortic lymph nodes, and the lymph nodes showed pheochromocytoma. Twenty-two months after the first operation, metastases to the left...
Alberto Biggi et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 683-690 (2013-03-22)
At present, there are no standard criteria that have been validated for interim PET reporting in lymphoma. In 2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville, France, proposed to develop simple and reproducible rules for...
Kamila Koprowska et al.
Postepy higieny i medycyny doswiadczalnej (Online), 65, 734-751 (2011-12-17)
Melanoma is a tumour derived from melanocytes, cells of neuroectodermal origin. Melanoma treatment represents a challenge to oncologists due to its aggressive course and early and multiple metastases. Surgical excision of lesions is a highly effective intervention, but only in...
Jie Wang et al.
Cancer chemotherapy and pharmacology, 72(1), 147-158 (2013-05-07)
Recent studies have reported that miR-181b contributes to chemoresistance in several cancer types and functions as a tumor suppressor in glioma. This study aimed to explore whether miR-181b could enhance the chemotherapeutic effect of temozolomide in glioma cells and sought...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.